Baker Tilly Wealth Management LLC Trims Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Baker Tilly Wealth Management LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 18.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,416 shares of the company’s stock after selling 1,902 shares during the period. Baker Tilly Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $724,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S during the second quarter valued at about $25,000. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at approximately $28,000. Abound Wealth Management lifted its holdings in Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares in the last quarter. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $42,000. Finally, Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $48,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NVO has been the subject of several research analyst reports. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Trading Up 1.6 %

Shares of NVO stock traded up $1.33 on Friday, reaching $86.97. 2,048,832 shares of the company’s stock were exchanged, compared to its average volume of 6,582,367. The company’s fifty day simple moving average is $100.86 and its 200 day simple moving average is $119.79. Novo Nordisk A/S has a 52 week low of $81.50 and a 52 week high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $390.28 billion, a PE ratio of 28.15, a P/E/G ratio of 1.37 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.